Clinical Trial Update: Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated osimertinib as first-line therapy in locally advanced or metastatic non-small cell lung cancer patients with EGFR mutations (includ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: MedSIR | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-01-28